Ramy Rahme

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study.

Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 07, 2026

T-Cell Acute Lymphoblastic Leukemia in a Young Patient With Andersen-Tawil Syndrome Successfully and Safely Treated With Intensive Chemotherapy Including Potential Precipitating Drugs: A Case Report After 3.5 Years of Follow-up.

T-Cell Acute Lymphoblastic Leukemia in a Young Patient With Andersen-Tawil Syndrome Successfully and Safely Treated With Intensive Chemotherapy Including Potential Precipitating Drugs: A Case Report After 3.5 Years of Follow-up.

Journal: EJHaem
Published: April 07, 2026

Plasmablastic Transformation of CLL/SLL: The Role of Early NGS Diagnosis and Targeted Multimodal Therapy.

Plasmablastic Transformation of CLL/SLL: The Role of Early NGS Diagnosis and Targeted Multimodal Therapy.

Journal: Diagnostics (Basel, Switzerland)
Published: December 05, 2025

An unusual case of basophilic meningitis revealing a chronic-phase chronic myeloid leukemia: a report after almost three years of follow-up.

An unusual case of basophilic meningitis revealing a chronic-phase chronic myeloid leukemia: a report after almost three years of follow-up.

Journal: Haematologica
Published: October 28, 2025

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Journal: HemaSphere
Published: July 25, 2025

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML.

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML.

Journal: HemaSphere
Published: January 02, 2025

Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World Analysis.

Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World Analysis.

Journal: EJHaem
Published: November 28, 2024

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.

Journal: Blood advances
Published: July 19, 2024

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

Journal: Journal of clinical medicine
Published: December 16, 2023

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type.

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type.

Journal: EMBO reports
Published: July 28, 2023

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Journal: Biomedicines
Published: March 16, 2023

Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Journal: Leukemia
Published: November 17, 2021
Showing 1-12 of 29

Last Updated: 09/26/2026